As Senior Director, Lead Development at Life Edit Therapeutics, Michael specializes in using protein engineering and bioconjugation to create novel therapeutics and utilizes his interdisciplinary background to evaluate and optimize them.
He previously held several positions at early-stage life sciences companies, including Applied Molecular Transport and Amunix, and focused on advancing delivery technologies for protein-based therapeutics.
Michael received his Ph.D. in Chemistry from the University of California, Berkeley, where he developed new methods to study cell signaling at membrane-membrane interfaces. Michael also holds a B.A. in Biochemistry and Molecular Biology from Boston University.
